| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/25/2006 | US7034039 Fused heterocyclic compounds |
| 04/25/2006 | US7034038 Gastrointestinal disorders; antiulcer agents caused by Helicobacter |
| 04/25/2006 | US7034037 Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin |
| 04/25/2006 | US7034036 Concurrent administering a central nervous system activator and preventor of drug transporter; pain therapy |
| 04/25/2006 | US7034035 Having a high residual activity, greater activity at lower application rates, curative activity, and a broader spectrum of efficacy; heterocyclic aromatic amides having a hydroxy group adjacent to the amide functionality |
| 04/25/2006 | US7034034 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives |
| 04/25/2006 | US7034033 Substituted quinazolinone compounds |
| 04/25/2006 | US7034032 1,2,3-triazolo(4,5-d)pyrimidine compounds used to treat cardiovascular disorders |
| 04/25/2006 | US7034031 Modulators of TNF-α signaling |
| 04/25/2006 | US7034030 Pyralopyridines, process for their preparation and use as therapeutic compounds |
| 04/25/2006 | US7034029 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| 04/25/2006 | US7034028 Treatment of inflammatory disorders |
| 04/25/2006 | US7034027 Method of treating a male or female animal in the treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising treating said animal with an effective amount of a pharmaceutical composition with carriers |
| 04/25/2006 | US7034026 serine/threonine kinase inhibitors; 2,3-diphenylquinoxalines in which at least one of the phenyls is substituted with an amine group, particularly 2-[4-(2-aminoprop-2-yl)phenyl]-3-phenylquinoxaline; treating cancer |
| 04/25/2006 | US7034025 Administering to a mammal an effective dose of a cysteine derivatives containing heteroaromatic group for the treatment of arterial tension, embryogenesis, oncogenesis, diabetes, cell proliferation, and other diseases |
| 04/25/2006 | US7034024 Synergistic mixture of 7-(2-amino-1-oxo-3-thiopropyl)-8-((cyclomethyl)-2-phenyl)-5,6,7,8-tetrahydroimidazolo(1,2-a)pyrazine and cisplatin |
| 04/25/2006 | US7034023 Antidepressants, anxiolytic agents; corticotropin releasing factor receptor antagonist |
| 04/25/2006 | US7034022 Proteases, kinases enzyme inhibitors; cardiovascular disorders; central nervous system disorders; antiinflammatrory agents; bone disorders; infections |
| 04/25/2006 | US7034021 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses |
| 04/25/2006 | US7034020 inactivators of antigen-specific T cells; increased half-life |
| 04/25/2006 | US7034019 Prodrugs of HIV replication inhibiting pyrimidines |
| 04/25/2006 | US7034018 Substituted pyrrole mannich bases to combat pain and allergic reactions |
| 04/25/2006 | US7034017 Substituted oxazolidinones and their use in the field of blood coagulation |
| 04/25/2006 | US7034016 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives |
| 04/25/2006 | US7034015 Interleukin 1 beta and tumour necrosis factor alpha inhibitors |
| 04/25/2006 | US7034014 Phosphonate compounds |
| 04/25/2006 | US7034013 Injectable sedative; mixture of propofol and sulfonated cyclodextrin |
| 04/25/2006 | US7034012 Administering ascorbic acid, or salt thereof, in mixture with carnitine compound |
| 04/25/2006 | US7034011 Using astaxanthin; tablet or enteric coated capsules |
| 04/25/2006 | US7034008 Unitary catheter drug delivery device for delivering polynucleotide to cardiac tissue of the patient, capable of modulating an electrical property of the heart, and designed to suppress K channels; electrode to detect position of the device within the patient |
| 04/25/2006 | US7034007 Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion |
| 04/25/2006 | US7034006 Use of lipid conjugates in the treatment of disease |
| 04/25/2006 | US7034005 Use of macrolide derivatives such as 6,15,16-Trioxatricyclo(10.2.1.11,4) hexadecane, erythromycin derivative |
| 04/25/2006 | US7033999 Muscle relaxants; anticoagulants; cardiovascular disorders |
| 04/25/2006 | US7033996 Hypercalcemia therapy; administering a protein which controls hydrolasase enzyme |
| 04/25/2006 | US7033794 Basolateral sorting signal and inhibitors thereof |
| 04/25/2006 | US7033779 Method for preparing steroids modified by yeast fermentation |
| 04/25/2006 | US7033755 Diagnostics and therapeutics for glaucoma |
| 04/25/2006 | US7033617 Use of Anoectochilus formosanus plant extracts and their derived fractions as herbal medicines or nutraceutical supplements for chemoprevention or treatment of human malignancies |
| 04/25/2006 | US7033616 Extracts, compounds and pharmaceutical compositions having anti-diabetic activity and their use |
| 04/25/2006 | US7033612 Composition and method for treating age-related disorders |
| 04/25/2006 | US7033607 Gene therapy; complexing nucleic acid and polymer |
| 04/25/2006 | US7033606 Pharmaceutical composition intended in particular for the prevention and the treatment of radiomucositis and chemomucositis |
| 04/25/2006 | US7033605 performing an ocular transplant procedure; implanting in the eye a biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer. |
| 04/25/2006 | US7033604 Composition for topical administration |
| 04/25/2006 | US7033599 Injectable compositions for the controlled delivery of pharmacologically active compound |
| 04/25/2006 | US7033594 Method of treatment using ligand-immunogen conjugates |
| 04/25/2006 | US7033588 combination of coenzyme Q and a surfactant can prevent ascites even when administering in a small dose and within a short period of time |
| 04/25/2006 | US7033584 Growing Thraustochytrium, Schizochytrium, and/or mixtures in a culture medium containing a non-chloride sodium salt, e.g., sodium sulfate; microfloral biomass; aquaculture of larval shrimp, rotifers, molluscs; extruded food with flaxseed meal |
| 04/25/2006 | US7033583 A water soluble polymer conjugated drug containing mercaptan group; controlled pharmacokinetics and improved bioavailability, relative to unmodified bioactive materials |
| 04/25/2006 | US7033582 Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 04/25/2006 | US7033580 Hair-growing agent |
| 04/25/2006 | US7033578 Antimycotic nail varnish composition |
| 04/25/2006 | US7033575 Delivery of physiologically active compounds through an inhalation route |
| 04/25/2006 | CA2522899C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| 04/25/2006 | CA2521956C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| 04/25/2006 | CA2521908C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| 04/25/2006 | CA2521891C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| 04/25/2006 | CA2521887C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| 04/25/2006 | CA2521833C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| 04/25/2006 | CA2521828C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| 04/25/2006 | CA2521792C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| 04/25/2006 | CA2521776C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| 04/25/2006 | CA2493827A1 Natural product derivatives as food supplements and pharmaceuticals |
| 04/25/2006 | CA2438097C Cannabinoids pharmaceutical formulations |
| 04/25/2006 | CA2433035C Pharmaceutical compositions comprising amlodipine maleate |
| 04/25/2006 | CA2410745C Process for converting the carbonyl function in position 4" of the cladinose unit of an aza-macrolide into an amine derivative |
| 04/25/2006 | CA2265766C Rapidly disintegrating pellets |
| 04/25/2006 | CA2264687C Permeation enhancers for transdermal drug delivery compositions, devices, and methods |
| 04/25/2006 | CA2256712C Stable, non-hygroscopic salts of l(-)carnitine and alkanoyl l(-)carnitines, a process for their preparation and solid, orally administrable compositions containing such salts |
| 04/25/2006 | CA2251949C Use of lofexidine in the manufacture of a medicament for treating attention deficit hyperactive disorder |
| 04/25/2006 | CA2237313C Aromatic carboxylic acid esters, the production of same and use of same as medicaments |
| 04/25/2006 | CA2194885C Substituted benzamidines, their preparation and their use as pharmaceutical compounds |
| 04/25/2006 | CA2189525C 2-(aminomethyl)-3,4,7,9-tetrahydro-2h-pyrano-[2,3e]indol-8-ones and derivatives |
| 04/25/2006 | CA2141039C Surfactant free aerosol formulations containing beclomethasone dipropionate |
| 04/25/2006 | CA2126929C Non-reducing oligosaccharide and its production and use |
| 04/21/2006 | CA2493831A1 Amino acid esters as nutrient supplements and methods of use |
| 04/21/2006 | CA2493398A1 Nutritional and food supplement preparation comprising creatine and orotic acid complexes, derivatives and analogs |
| 04/20/2006 | WO2006042324A2 Antifungal composition applicable to body tissue, preferably nails |
| 04/20/2006 | WO2006042289A2 Substituted biaryl quinolin-4-ylamine analogues |
| 04/20/2006 | WO2006042278A1 Compounds and methods of treating insulin resistance and cardiomyopathy |
| 04/20/2006 | WO2006042249A2 Methods and compositions for treating migraine pain |
| 04/20/2006 | WO2006042200A2 Method for synthesis of beta-glucans |
| 04/20/2006 | WO2006042195A1 Alkyl benzamides |
| 04/20/2006 | WO2006042186A2 Gastrointestinal examination preparation |
| 04/20/2006 | WO2006042172A2 Gender differences in experimental aortic aneurysm formation |
| 04/20/2006 | WO2006042150A1 Diaminoalkane aspartic protease inhibitors |
| 04/20/2006 | WO2006042104A2 Calixarene-based peptide conformation mimetics, methods of use, and methods of making |
| 04/20/2006 | WO2006042102A2 Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| 04/20/2006 | WO2006042100A2 Method for the treatment of polycystic kidney disease |
| 04/20/2006 | WO2006042056A2 Methods and compositions for enzyme-specific activation of carbohydrate-conjugated prodrugs |
| 04/20/2006 | WO2006042021A2 Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
| 04/20/2006 | WO2006042007A2 Chromenone compounds as calcilytics |
| 04/20/2006 | WO2006041985A2 Thienopyridinone compounds and methods of treatment |
| 04/20/2006 | WO2006041976A1 Combination of organic compounds |
| 04/20/2006 | WO2006041975A1 Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and method of making them |
| 04/20/2006 | WO2006041974A1 Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure |
| 04/20/2006 | WO2006041968A1 Reversed pyrimidinone compounds as calcilytics |
| 04/20/2006 | WO2006041961A1 Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same |
| 04/20/2006 | WO2006041941A2 Use of aromatase inhibitors for the treatment of ectopic pregnancy |